Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders (INOT)

This study has been completed.
Sponsor:
Collaborator:
National Alliance for Research on Schizophrenia and Depression
Information provided by (Responsible Party):
Eric Hollander, Montefiore Medical Center
ClinicalTrials.gov Identifier:
NCT01337687
First received: December 15, 2010
Last updated: May 27, 2014
Last verified: May 2014

December 15, 2010
May 27, 2014
October 2009
December 2013   (Final data collection date for primary outcome measure)
Clinical Global Impressions Scale- Severity and Improvement [ Time Frame: Week 8 (end of study) ]
Rating Scale that utilizes direct observation, scales and patient report to inform clinical judgment. A form of CGI that targets social functioning will be used as the primary outcome measure. Semi-structured interview.
Same as current
Complete list of historical versions of study NCT01337687 on ClinicalTrials.gov Archive Site
  • Number of Adverse Events in Patients with Oxytocin verse Placebo [ Time Frame: Weeks 2,4, 6 and 8 ]
    Adverse events will be recorded for each subject by the study psychiatrist at the study visit in weeks 2 -8. Although no formal statistical analyses will be completed, results from Intranasal Oxytocin groups will be compared to the placebo group.
  • Yale Brown Obsessive Compulsive Scale (YBOCS) [ Time Frame: baseline, weeks 2,4,6,8 ]
    Clinician-Rated questionnaire measuring the time spent, distress,interference, resistance, and control in relation to obsessions and compulsions based on a 5 point scale.
  • Repetitive Behavior Scale - Revised (RBS-R) [ Time Frame: Baseline, weeks 2,4,6,8 ]
    A clinical tool measuring repetitive behaviors specific to Autism Spectrum Disorder (ASD).
  • Diagnostic Analysis of Nonverbal Accuracy - 2 (DANVA-2) [ Time Frame: baseline and week 8 ]
    A clinical tool measuring emotion recognition through facial expression, voice and posture. This tool is commonly used to assess nonverbal processing abilities.
Same as current
Not Provided
Not Provided
 
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders
Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders

Autism Spectrum Disorder (ASD) is a developmental disorder characterized by abnormalities in speech and communication, impaired social functioning and repetitive behaviors and restricted interests. Oxytocin (OT) is peptide that is known for its peripheral effects on facilitating uterine contractions and milk let-down; however, studies, mainly with rodents and non-human primates, has found that OT is involved in affiliative behaviors, including sexual behavior, mother-infant and adult-adult pair-bond formation, separation distress, and other aspects of social attachment. Moreover, OT is known to play an important role in repetitive behaviors and stress reactivity. Given that repetitive behaviors and deficits in social interaction are core symptom domains of autism, and that OT is involved in the regulation of repetitive and affiliative behaviors, it is believed that OT may play a role in the etiology of autism. Moreover, preliminary data obtained by Hollander and colleagues suggests that OT may be of value in treating core autism symptoms. Specifically, synthetic oxytocin administered via intravenous infusion to adults with autism spectrum disorders (ASD) produced significant reductions in repetitive behaviors and facilitated social cognition/memory in a double-blind, placebo-controlled cross-over laboratory challenge.

Encouraged by these findings, the primary aim of this study is to investigate the safety and therapeutic efficacy of intranasal OT in treating repetitive behaviors and social functioning/cognitive deficits in adults with ASD. This research embraces a translational approach to develop a novel treatment for core ASD symptoms; given that there are currently no Food and Drug Administration (FDA) approved medication treatments for core ASD symptoms, this research addresses an important unmet need in the field. The goal of this study is to evaluate the safety and efficacy of repeated Intranasal Oxytocin Treatment (INOT)administration in adults with ASD.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Autism Spectrum Disorders
  • Drug: Intranasal Oxytocin
    Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
  • Drug: Placebo
    Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
  • Experimental: Oxytocin
    Intervention: Drug: Intranasal Oxytocin
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1
December 2013
December 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and Female
  • 18 to 55 years old
  • Meet DSM-IV, ADOS, and ADI-R standards for Autism Spectrum Disorder or Aspergers Syndrome
  • Have a high, normal or near normal IQ
  • Speak and Understand English fluently

Exclusion Criteria:

  • Born prior to 35 weeks gestational age
  • Any primary psychiatric diagnosis other than autism at the time of screening
  • Medical history of neurological disease
  • Medical history of known MRI/structural lesion of the brain
  • Patients who are pregnant
  • With a medical condition that might interfere with the conduct of the study, confound interpretation of study results or endanger their own well being
  • With evidence or history of malignancy or any significant hematological, endocrine, cardiovascular, respiratory, renal, hepatic or gastrointestinal disease
  • Taking psychoactive medications
  • Who plan to initiate or change nonpharmacologic interventions during the study course
  • Who are unable to tolerate venipuncture procedures for blood sampling
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01337687
NARSAD Award
No
Not Provided
Not Provided
Not Provided
Eric Hollander, Montefiore Medical Center
Montefiore Medical Center
National Alliance for Research on Schizophrenia and Depression
Principal Investigator: Eric Hollander, MD Montefiore Medical Center, Albert Einstein College of Medicine
Montefiore Medical Center
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP